Atsushi “Andy” Fujimoto, Mitsubishi Tanabe Pharma America president

FDA ap­proves oral for­mu­la­tion of old ALS drug, giv­ing pa­tients new treat­ment op­tion in sore­ly need­ed field

Much of the ALS drug news in re­cent months has fo­cused on Amy­lyx Phar­ma­ceu­ti­cals and its ex­per­i­men­tal pro­gram re­viewed by an FDA ad­vi­so­ry com­mit­tee in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.